RDUS Profile
Radius Health, Inc. (RDUS) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases. The company's lead product is TYMLOS (abaloparatide), a bone-building agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal women with osteoporosis at high risk of fracture.
TYMLOS is an injectable human parathyroid hormone-related peptide (PTHrP) analog. It has been shown to reduce the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Radius Health has also developed abaloparatide-SC, a once-daily injectable formulation of abaloparatide, which is approved for use in Canada, the European Union, and other countries.
In addition to its osteoporosis portfolio, Radius Health is developing a pipeline of therapeutics for endocrine-mediated diseases, including the investigational drug elacestrant, an oral selective estrogen receptor degrader for the treatment of estrogen receptor-positive, HER2-negative advanced breast cancer.
Based in Waltham, Massachusetts, Radius Health was founded in 2003 and went public in 2014. The company has collaborations with pharmaceutical companies including Takeda Pharmaceutical Company and Ipsen Biopharmaceuticals.
|
